• FluTrackers.com Inc. does not provide medical advice. Information on this web site is collected from various internet resources, and the FluTrackers board of directors makes no warranty to the safety, efficacy, correctness or completeness of the information posted on this site by any author or poster. The information collated here is for instructional and/or discussion purposes only and is NOT intended to diagnose or treat any disease, illness, or other medical condition. Every individual reader or poster should seek advice from their personal physician/healthcare practitioner before considering or using any interventions that are discussed on this website. By continuing to access this website you agree to consult your personal physican before using any interventions posted on this website, and you agree to hold harmless FluTrackers.com Inc., the board of directors, the members, and all authors and posters for any effects from use of any medication, supplement, vitamin or other substance, device, intervention, etc. mentioned in posts on this website, or other internet venues referenced in posts on this website.
  • We are not asking for any donations. Do not donate to any entity who says they are raising funds for us.

Development and applications of universal H7 subtype-specific antibodies for the analysis of influenza H7N9 vaccines

tetano

Editor, Senior Moderator
Vaccine. 2015 Jan 22. pii: S0264-410X(15)00053-5. doi: 10.1016/j.vaccine.2015.01.034. [Epub ahead of print]
[h=1]Development and applications of universal H7 subtype-specific antibodies for the analysis of influenza H7N9 vaccines.[/h] Gravel C[SUP]1[/SUP], Elmgren C[SUP]2[/SUP], Muralidharan A[SUP]3[/SUP], Hashem AM[SUP]4[/SUP], Jaentschke B[SUP]1[/SUP], Xu K[SUP]5[/SUP], Widdison J[SUP]2[/SUP], Arnold K[SUP]2[/SUP], Farnsworth A[SUP]1[/SUP], Rinfret A[SUP]1[/SUP], Van Domselaar G[SUP]6[/SUP], Wang J[SUP]5[/SUP], Li C[SUP]5[/SUP], Li X[SUP]7[/SUP].
[h=3]Author information[/h]

[h=3]Abstract[/h] H7N9 is a newly emerged avian influenza virus with a relatively high mortality rate in humans. At this time, there is no licensed vaccine for human protection. Development of analytical tools for H7N9 vaccine could facilitate vaccine development. Here, a universally conserved epitope in all H7 hemagglutinin (HA) sequences was identified through comprehensive bioinformatics analyses. The peptide epitope, RSGSSFYAEMK, (aa positions 149 to 159), is located on the head of the HA molecule. Antibodies generated against this universal H7 epitope were remarkably specific against H7 viral sequence with no detectable cross-reactivity to other HA subtypes. A new immunoblotting assay based on the universal H7 antibody was developed and compared with the traditional single radial immunodiffusion assay (SRID) for potency analyses of candidate H7N9 vaccines. This new assay was more sensitive and rapid compared to SRID. In addition to statistically acceptable precision and reproducibility, the new assay differs from many other alternative potency assays for influenza vaccine in that it is potentially stability-indicating, which is an important requirement for industry vaccine stability studies analyses. Furthermore, the robustness of this new assay was demonstrated by the quantitative determination of HA content in four H7N9 vaccines (split or inactivated) from different manufacturers.
Copyright ? 2015. Published by Elsevier Ltd.


[h=4]KEYWORDS:[/h] H7N9 influenza vaccine; Universal H7 epitope; Vaccine quantitation

PMID: 25620245 [PubMed - as supplied by publisher]
 
Back
Top Bottom